Literature DB >> 9519302

The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways.

J W Kelly1.   

Abstract

The conformational change hypothesis postulates that tertiary structural changes under partially denaturing conditions convert one of 17 normally soluble and functional human proteins into an alternative conformation that subsequently undergoes self-assembly into an amyloid fibril, the putative causative agent in amyloid disease. This hypothesis is consistent with Anfinsen's view that the tertiary structure of a protein is determined both by its sequence and the aqueous environment; the latter does not always favor the normally folded state. Unlike sickle cell hemoglobin assembly, where owing to a surface mutation, hemoglobin polymerizes in its normally folded conformation, amyloid proteins self-assemble as a result of the formation of an alternative tertiary structure-a conformational intermediate formed under partially denaturing conditions. The pathway by which an amyloidogenic protein assembles into amyloid fibrils appears to involve quaternary structural intermediates that assemble into increasingly complex quaternary structures, including amyloid protofilaments, which ultimately assemble into amyloid fibrils. Several recent studies have discussed the multi-step assembly pathway(s) characterizing amyloid fibril formation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9519302     DOI: 10.1016/s0959-440x(98)80016-x

Source DB:  PubMed          Journal:  Curr Opin Struct Biol        ISSN: 0959-440X            Impact factor:   6.809


  259 in total

1.  Conformational propagation with prion-like characteristics in a simple model of protein folding.

Authors:  P M Harrison; H S Chan; S B Prusiner; F E Cohen
Journal:  Protein Sci       Date:  2001-04       Impact factor: 6.725

Review 2.  Amyloid diseases: abnormal protein aggregation in neurodegeneration.

Authors:  E H Koo; P T Lansbury; J W Kelly
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-31       Impact factor: 11.205

3.  Equilibria and kinetics of folding of gelsolin domain 2 and mutants involved in familial amyloidosis-Finnish type.

Authors:  R L Isaacson; A G Weeds; A R Fersht
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

4.  WW: An isolated three-stranded antiparallel beta-sheet domain that unfolds and refolds reversibly; evidence for a structured hydrophobic cluster in urea and GdnHCl and a disordered thermal unfolded state.

Authors:  E K Koepf; H M Petrassi; M Sudol; J W Kelly
Journal:  Protein Sci       Date:  1999-04       Impact factor: 6.725

5.  Designing conditions for in vitro formation of amyloid protofilaments and fibrils.

Authors:  F Chiti; P Webster; N Taddei; A Clark; M Stefani; G Ramponi; C M Dobson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

6.  Cryo-electron microscopy structure of an SH3 amyloid fibril and model of the molecular packing.

Authors:  J L Jiménez; J I Guijarro; E Orlova; J Zurdo; C M Dobson; M Sunde; H R Saibil
Journal:  EMBO J       Date:  1999-02-15       Impact factor: 11.598

7.  A solvent model for simulations of peptides in bilayers. II. Membrane-spanning alpha-helices.

Authors:  R G Efremov; D E Nolde; G Vergoten; A S Arseniev
Journal:  Biophys J       Date:  1999-05       Impact factor: 4.033

Review 8.  De novo design of helical bundles as models for understanding protein folding and function.

Authors:  R B Hill; D P Raleigh; A Lombardi; W F DeGrado
Journal:  Acc Chem Res       Date:  2000-11       Impact factor: 22.384

9.  Formation of insulin amyloid fibrils followed by FTIR simultaneously with CD and electron microscopy.

Authors:  M Bouchard; J Zurdo; E J Nettleton; C M Dobson; C V Robinson
Journal:  Protein Sci       Date:  2000-10       Impact factor: 6.725

10.  Ultrastructural organization of amyloid fibrils by atomic force microscopy.

Authors:  A K Chamberlain; C E MacPhee; J Zurdo; L A Morozova-Roche; H A Hill; C M Dobson; J J Davis
Journal:  Biophys J       Date:  2000-12       Impact factor: 4.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.